HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mirjana Urosevic Selected Research

Investigational Therapies (Experimental Therapy)

2/2006Standard and experimental therapy in cutaneous T-cell lymphomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mirjana Urosevic Research Topics

Disease

17Neoplasms (Cancer)
05/2008 - 01/2002
8Melanoma (Melanoma, Malignant)
05/2008 - 01/2004
7Lymphoma (Lymphomas)
10/2007 - 01/2002
6Basal Cell Carcinoma (Rodent Ulcer)
12/2007 - 10/2003
5Skin Neoplasms (Skin Cancer)
12/2007 - 01/2002
3Neoplasm Metastasis (Metastasis)
01/2008 - 08/2004
3Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
02/2006 - 03/2004
2Carcinogenesis
01/2009 - 08/2004
2Lung Neoplasms (Lung Cancer)
01/2003 - 05/2002
1Erythema
01/2009
1Inflammation (Inflammations)
01/2009
1Skin Diseases (Skin Disease)
12/2007
1Bowen's Disease (Disease, Bowen)
08/2005
1Hodgkin Disease (Hodgkin's Disease)
01/2005
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2004
1T-Cell Lymphoma (Lymphoma, T Cell)
03/2004
1Mycosis Fungoides
01/2003
1Human Influenza (Influenza)
01/2003
1Carcinoma (Carcinomatosis)
05/2002
1Breast Neoplasms (Breast Cancer)
03/2002
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2002
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2002

Drug/Important Bio-Agent (IBA)

7HLA-G Antigens (HLA G)IBA
02/2008 - 01/2002
7Imiquimod (Aldara)FDA LinkGeneric
12/2007 - 01/2003
5Proteins (Proteins, Gene)FDA Link
12/2007 - 01/2002
4HLA Antigens (Human Leukocyte Antigens)IBA
02/2008 - 03/2002
4Neoplasm Antigens (Tumor Antigens)IBA
02/2007 - 01/2002
4AntigensIBA
07/2005 - 01/2002
4Interleukin-10 (Interleukin 10)IBA
03/2004 - 01/2002
3LigandsIBA
12/2007 - 03/2002
3Peptides (Polypeptides)IBA
12/2006 - 05/2002
3CytokinesIBA
08/2005 - 10/2003
2Toll-Like Receptor 7IBA
02/2008 - 12/2007
2Differentiation AntigensIBA
02/2007 - 12/2006
2OligonucleotidesIBA
08/2005 - 08/2004
2Monophenol Monooxygenase (Tyrosinase)IBA
07/2005 - 08/2004
2MART-1 AntigenIBA
07/2005 - 08/2004
2InterferonsIBA
09/2004 - 05/2004
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2009
1TeaIBA
01/2009
1ThymidineIBA
01/2009
1Dacarbazine (DIC)FDA LinkGeneric
05/2008
1Interleukin-2 (IL2)IBA
05/2008
1Biological ProductsIBA
05/2008
1S100 Proteins (S 100 Protein)IBA
01/2008
1Notch1 ReceptorIBA
12/2007
1Jagged-1 ProteinIBA
12/2007
1Pharmaceutical PreparationsIBA
06/2007
1HLA-A*02:01 antigenIBA
12/2006
1Interferon-gamma (Interferon, gamma)IBA
09/2004
1methionine-enkephalin receptorIBA
08/2004
1Messenger RNA (mRNA)IBA
05/2004
1Immunoglobulins (Immunoglobulin)IBA
03/2004
1Fas Ligand Protein (Fas Ligand)IBA
10/2003
1InterleukinsIBA
10/2003
1Cell Adhesion MoleculesIBA
10/2003
1Death Domain ReceptorsIBA
10/2003
1RetinoidsIBA
01/2003
1EpitopesIBA
01/2003
1influenza matrix peptide (58-66)IBA
01/2003
1ChromiumIBA
05/2002
1Epithelial Cell Adhesion MoleculeIBA
05/2002
1SilverIBA
01/2002

Therapy/Procedure

4Aftercare (After-Treatment)
10/2007 - 10/2003
3Therapeutics
06/2007 - 01/2002
3Immunotherapy
07/2005 - 01/2002
3Radiotherapy
01/2005 - 12/2003
1Injections
05/2008
1Drug Therapy (Chemotherapy)
02/2008
1Investigational Therapies (Experimental Therapy)
02/2006